GCG and Other metabolic disease: It might be useful, to explore more in depth which are the differently expressed miRNAs in response to GLP1 (physiological conditions) and GLP1-R agonists (supra-physiological levels), to better understand which miRNAs have a potential impact on metabolic diseases.